首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   10033篇
  免费   720篇
  国内免费   360篇
耳鼻咽喉   59篇
儿科学   67篇
妇产科学   143篇
基础医学   1312篇
口腔科学   271篇
临床医学   580篇
内科学   1659篇
皮肤病学   198篇
神经病学   520篇
特种医学   192篇
外国民族医学   1篇
外科学   626篇
综合类   756篇
预防医学   691篇
眼科学   115篇
药学   2739篇
中国医学   635篇
肿瘤学   549篇
  2024年   5篇
  2023年   149篇
  2022年   229篇
  2021年   354篇
  2020年   305篇
  2019年   320篇
  2018年   345篇
  2017年   320篇
  2016年   323篇
  2015年   397篇
  2014年   744篇
  2013年   887篇
  2012年   693篇
  2011年   872篇
  2010年   649篇
  2009年   607篇
  2008年   676篇
  2007年   521篇
  2006年   402篇
  2005年   390篇
  2004年   287篇
  2003年   303篇
  2002年   233篇
  2001年   136篇
  2000年   122篇
  1999年   106篇
  1998年   90篇
  1997年   66篇
  1996年   66篇
  1995年   61篇
  1994年   56篇
  1993年   39篇
  1992年   49篇
  1991年   41篇
  1990年   27篇
  1989年   32篇
  1988年   22篇
  1987年   19篇
  1986年   25篇
  1985年   20篇
  1984年   20篇
  1983年   22篇
  1982年   24篇
  1981年   12篇
  1980年   7篇
  1979年   7篇
  1978年   11篇
  1977年   8篇
  1976年   5篇
  1974年   3篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
藏族药(以下简称藏药)“杂赤”又称“杂赤确”“杂赤巴帽卡”等,产于四川、西藏等地,是一种治疗肝胆疾病的常用藏药。通过梳理查阅有关文献与标准发现,“杂赤”可以按正品、副品(替代品)和类同品分类,也可以按黑、白品种分类。其基原包含菊科12属约30种植物,涉及风毛菊属、苦荬菜属、小苦荬属及岩参属植物,各属植物功能主治基本相同。“杂赤”的品种整理、质量比较、药用历史和现状总结能够为“杂赤”的合理使用提供参考。  相似文献   
2.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action.  相似文献   
3.
《Value in health》2022,25(2):178-184
ObjectivesThe ALIC4E trial has shown that oseltamivir reduces recovery time while increasing the risk of nausea. This secondary analysis of the ALIC4E trial aimed to determine the gain in quality-adjusted life-years (QALYs) associated with adding oseltamivir to usual primary care in patients presenting with influenza-like illness (ILI).MethodsPatients with ILI were recruited during the influenza season (2015-2018) in 15 European countries. Patients were assigned to usual care with or without oseltamivir through stratified randomization (age, severity, comorbidities, and symptom onset). Patients’ health status was valued with the EQ-5D and visual analog scale (VAS) for up to 28 days. Average EQ-5D and VAS scores over time were estimated for both treatment groups using one-inflated beta regression in children (<13 years old) and adults (≥13 years old). QALY gain was calculated as the difference between the groups. Sensitivity analysis considered the value set to convert EQ-5D answers to summary scores and the follow-up period.ResultsIn adults, oseltamivir gained 0.0006 (95% confidence interval 0.0002-0.0010) QALYs, whereas no statistically significant gain was found in children (14-day follow-up, EQ-5D). QALY gains were statistically significant in patients aged ≥65 years, patients without relevant comorbidities, or patients experiencing symptoms for ≤48 hours. Using VAS and accounting for 28-day follow-up resulted in higher QALY gain.ConclusionsQALY gain owing to oseltamivir is limited compared with other diseases, and its clinical meaningfulness remains to be determined. Further analysis is needed to evaluate whether QALY gain and its impact on ILI treatment cost render oseltamivir cost-effective.  相似文献   
4.
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis.  相似文献   
5.
《Saudi Pharmaceutical Journal》2022,30(11):1665-1671
5-fluorouracil (5FU) is widely used to treat colorectal cancer (CC) and its main mechanisms of anticancer action are through generation of ROS which often result in inflammation. Here, we test the effect of Lycopene against 5FU in Caco2 cell line. Caco2 cells were exposed to 3 µg/ml of 5FU alone or with 60, 90, 120 µg/ml of lycopene. This was followed by assessment of cytotoxicity, oxidative stress, and gene expression of inflammatory genes. Our findings showed that Lycopene and 5FU co-exposure induced dose-dependent cytotoxic effect without compromising the membrane integrity based on the LDH assay. Lycopene also significantly enhanced 5FU-induced SOD activity and GSH level compared to control for all mixture concentrations (p < 0.01). Lycopene alone and combination with 5FU-induced expression of IL-1β, TNF-α, and IL-6. Furthermore, IFN-γ expression was significantly enhanced by only mixture of lycopene (90 µg/ml) and 5FU (p < 0.05). In conclusion, Lycopene supplementation with 5FU therapy resulted in improvement in antioxidant parameters such as catalase and GSH levels giving the cell capacity to cope with 5FU-mediated oxidative stress. Lycopene also enhanced IFN-γ expression in the presence of 5FU, which may activate antitumor effects further enhancing the cancer killing effect of 5FU.  相似文献   
6.
7.
目的 探讨扶正化瘀方含药血清对肝星状细胞(HSC)激活素A(activinA)/smad信号通路活化的影响。方法 20只SD大鼠按照随机数字表法分为对照组及扶正化瘀(Fzhy)-低、中、高剂量含药血清组,每组5只,分别以蒸馏水,0.75、1.5、3.0 g/kg扶正化瘀溶液(扶正化瘀胶囊药物粉末与蒸馏水配制)灌胃1次/d,连续3 d,取血制备空白血清(对照组)和含药血清。以大鼠HSC-T6细胞为研究对象,分别用5%、10%、20%体积分数的各组含药血清培养细胞。CCK-8检测细胞存活率,选取细胞存活率在50%左右的体积分数重新分为对照组及Fzhy-低、中、高剂量组。流式细胞术检测细胞周期及凋亡率、线粒体膜电位变化和活性氧(ROS)水平;实时荧光定量聚合酶链反应检测细胞中activinA、smad3、samd7、核因子(NF)-κB的mRNA水平;蛋白质印迹法检测细胞中activinⅡA受体(ActRⅡA)、smad3、NF-κB p65、胱天蛋白酶(caspase)-3的蛋白水平。结果 各扶正化瘀含药血清组的细胞存活率均低于对照组(P<0.05),选择体积分数为10%的含药血清进行后续实验。对照组和各扶正化瘀方含药血清组细胞周期和凋亡率差异均无统计学意义。对照组及Fzhy-低、中、高剂量组细胞内ROS水平及线粒体膜电位水平降低比例逐次升高(P<0.05)。与对照组比较,Fzhy-中、高剂量组smad3 mRNA表达水平降低,smad7 mRNA升高,Fzhy-低、中、高剂量组NF-κB、activinA mRNA,smad3、NF-κB p65、ActRⅡA蛋白表达水平降低,Fzhy-低剂量组、中剂量组caspase-3蛋白表达水平升高(P<0.05);与Fzhy-低剂量组相比,Fzhy-中、高剂量组smad3 mRNA表达水平降低,Fzhy-中剂量组activinA及smad7 mRNA升高(P<0.05)。结论 扶正化瘀方含药血清可通过影响HSC-T6细胞增殖、参与细胞的氧化应激以及调节细胞activinA/smad信号转导通路来实现抗纤维化作用。  相似文献   
8.
Mammary epithelial cells (MECs) play an important role against Streptococcus uberis infection which is one of the main causes of bovine mastitis and a potential threat to human health. Toll-like receptors (TLRs) and their mediated signaling pathways are critical in both innate and infection responses, yet their roles in anti-S. uberis infection in MECs remains poorly defined. In this work we investigated the regulatory mechanisms of TLR2 in inflammatory responses, where WT and TLR2−/− mice were euthanized at 15–18 days gestation, and mammary gland tissues were collected aseptically. The mouse MECs (MMECs) were isolated by combined digestion with type I collagenase, hyaluronidase and trypsin. We challenged MMECs with S. uberis and quantified antioxidant capacity as well as reactive oxygen species (ROS), proinflammatory cytokines and cell damage at different times. The loss of TLR2 function in MMECs results in more serious cell damage, increased cell adhesion, and significantly decreased ROS and mitochondrial ROS (mROS) with bactericidal function in response to S. uberis infection. Moreover, it was observed that the antioxidant capacity declined, and the production of TLR2-mediated cytokines (except CXC ligand 15) also were reduced. We demonstrated that TLR2 can mediate cellular anti-infective processes in MMECs by regulating the production of ROS and mROS and the secretion of cytokines. The results suggest an unpredicted role of TLR2 in MMECs in response to S. uberis infection.  相似文献   
9.
目的:研究肝切除术后小鼠肝再生过程中锰超氧化物歧化酶(MnSOD)的表达及其活性的变化,探讨MnSOD在肝再生中的作用。方法:采用经典小鼠肝切除模型,将38只雄性BALB/c小鼠,随机分为30%肝切除组(30% PH组)18只,70%肝切除组(70% PH组)18只,以及对照组2只。2个肝切除组分别于术后6 h和1、2、3、5、7 d这6个时间点随机各抽取3只小鼠处死,对照组小鼠在行假手术后即处死。取肝组织,制备冰冻切片使用DHE染色法在激光共聚焦显微镜下检测活性氧(ROS)水平,实时荧光定量PCR检测小鼠肝组织中MnSOD mRNA表达水平,Western blot检测小鼠肝组织中MnSOD蛋白的表达水平,采用MnSOD试剂盒检测小鼠肝组织中的MnSOD活性。结果:肝切除术后,与对照组相比,30% PH组小鼠肝组织ROS水平在术后6 h和1 d增加,MnSOD mRNA表达水平增加(P < 0.05),MnSOD蛋白含量无显著变化(P > 0.05);MnSOD的活性在术后第1和2天较高,第3和5天较低,第7天恢复。70% PH组小鼠肝组织ROS水平在术后第1~5天均升高,MnSOD mRNA的水平先下降后逐渐恢复,MnSOD的蛋白含量降低,MnSOD的活性在术后第6小时和1天增加,第2~7天均处于降低状态(P均 < 0.05)。结论:在肝切除术后小鼠的肝再生过程迅速启动,尤其是在70% PH后肝细胞迅速增殖,并在术后一段时间逐渐恢复到静息状态,其机制可能与MnSOD含量和活性的下调从而导致ROS升高有关。  相似文献   
10.
目的研究五味子醇甲(SCH)对APP/PS1双转基因痴呆小鼠行为学和NF-κB p65的影响。方法将35只APP/PS1双转基因痴呆小鼠随机分为模型(APP/PS1)组、五味子醇甲(SCH+APP/PS1)组;另以同背景同月龄的C 57 BL/6 J阴性小鼠为空白(WT)组。SCH+APP/PS1组给予SCH悬浊液灌胃(2.6 mg·kg^-1·d^-1),模型组和空白组给予等量蒸馏水灌胃。各组灌胃30 d进行Mirror水迷宫空间探索试验后取材。HE染色法观察皮层及海马CA1区神经细胞的形态结构。运用DCFH-DA法检测脑组织活性氧(ROS)含量。Western印迹检测法检验磷酸化核转录因子(NF-κB p65,pp65)的表达。结果与APP/PS 1组相比,APP/PS 1+SCH组有效区停留距离及时间明显延长,差异有统计学意义(P<0.05,P<0.01);APP/PS 1+SCH组穿越有效区次数和平台区停留距离增加,均差异有统计学意义(P<0.01)。APP/PS 1+SCH组HE染色观察皮层有部分神经细胞萎缩、减少,较APP/PS1组明显好转,海马细胞排列整齐度尚可、较均匀。与APP/PS1组相比,APP/PS1+SCH组能降低ROS含量,差异有统计学意义(P<0.05)。APP/PS 1+SCH组皮层及海马pp65蛋白相对表达量下调(P<0.05,P<0.01)。结论SCH可能通过降低ROS含量和抑制pp65保护脑组织形态结构和提高APP/PS1鼠空间探索记忆能力。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号